KRAS and neoplasm: Clinical trials with BI-2865 are currently not yet ongoing, but in preclinical stage, BI-2493, which is a structural analog of BI-2865 that was optimized for in vivo administration, attenuated tumor growth in mice bearing KRAS G12C, G12D, G12V, and A146V mutant models (30).